FLT3 and acute myeloid leukemia: Crenolanib, a highly potent and specific second generation FLT3 TKI designed to target both ITD and TKD mutations, has also been studied in de novo FLT3 AML and is effective against D835 mutations, which confer resistance to sorafenib and quizartinib [20].